UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

To Serve Those Who Are Handicapped: A Special Model Construct for Career Education

Illinois Career Education Journal, 1974, Vol.31 (4), p.2

Szoke, Claire

1974

Volltextzugriff (PDF)

The Miau Manuscript of Benito Pérez Galdós: A Critical Study

Hispanófila, 1966 (28), p.63-64

Szoke, Claire

1966

Volltextzugriff (PDF)

Reseña (Book Review)

Hispanófila, 1966, Vol.28, p.63

Szoke, Claire

1966

Volltextzugriff (PDF)

Promoting personal, social, and career development for elementary school children with handicaps

International journal of rehabilitation research, 1982-06, Vol.5 (2), p.257-257

1982

Volltextzugriff (PDF)

ANTICIPATIONS OF THE NOVENTAYOCHISTA ANALYSIS OF THE PROBLEM OF SPAIN IN THE WORK OF GALDOS PRIOR TO 1898

SZOKE, CLAIRE OLSON

1969

Volltextzugriff (PDF)

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial

JAMA oncology, 2018-05, Vol.4 (5), p.652

2018

Volltextzugriff (PDF)

Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

Blood advances, 2022-06, Vol.6 (11), p.3440-3450

2022

Volltextzugriff (PDF)

A Multilevel Functional Study of a SNAP25 At-Risk Variant for Bipolar Disorder and Schizophrenia

The Journal of neuroscience, 2017-10, Vol.37 (43), p.10389-10397

2017

Volltextzugriff (PDF)

Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia: The FACE-SZ Cohort

The journal of clinical psychiatry, 2018-09, Vol.79 (6)

2018

Volltextzugriff (PDF)

Many people with chronic lymphocytic leukemia or small lymphocytic lymphoma benefit from ibrutinib treatment up to 8 years: a plain language summary

Future oncology (London, England), 2022-12, Vol.18 (37), p.4047-4057

2022

Volltextzugriff (PDF)

Prognostic role of beta-2 microglobulin (B2M) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients (pts) treated with ibrutinib (ibr)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.7521-7521

2018

Volltextzugriff (PDF)

Sepsis-related deaths in the at-risk population on the wards: attributable fraction of mortality in a large point-prevalence study

BMC research notes, 2018-10, Vol.11 (1), p.720-720, Article 720

2018

Volltextzugriff (PDF)

Outcomes in patients with myelofibrosis and RBC-transfusion dependence in the phase III PERSIST-1 study of pacritinib vs. best available therapy

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.7066-7066

2016

Volltextzugriff (PDF)

Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): 60 week follow-up of the phase III PERSIST-1 trial

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.7065-7065

2016

Volltextzugriff (PDF)

Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Outcomes in patients (pts) with baseline (BL) thrombocytopenia

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.7011-7011

2016

Volltextzugriff (PDF)

Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF)

Journal of clinical oncology, 2015-06, Vol.33 (18_suppl), p.LBA7006-LBA7006

2015

Volltextzugriff (PDF)

Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.LBA7006-LBA7006

2015

Volltextzugriff (PDF)

Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings

Molecular psychiatry, 2021-08, Vol.26 (8), p.4529-4543

2021

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19)
Mit Volltextzugriff
(16)

Publikationsform

Sprache

Englisch
(20)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(8)
Science & Technology
(8)
Humans
(6)
Female
(4)
Male
(4)
Adult
(3)
Aged
(3)
Middle Aged
(3)
Pyrimidines - Adverse Effects
(3)
Treatment Outcome
(3)
Age
(2)
Bridged-Ring Compounds - Administration & Dosage
(2)
Bridged-Ring Compounds - Adverse Effects
(2)
Cross-Sectional Studies
(2)
Follow-Up Studies
(2)
Hematology
(2)
Neurosciences
(2)
Neurosciences & Neurology
(2)
Oncology
(2)
Primary Myelofibrosis - Drug Therapy
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

To Serve Those Who Are Handicapped: A Special Model Construct for Career Education

The Miau Manuscript of Benito Pérez Galdós: A Critical Study

Reseña (Book Review)

Promoting personal, social, and career development for elementary school children with handicaps

ANTICIPATIONS OF THE NOVENTAYOCHISTA ANALYSIS OF THE PROBLEM OF SPAIN IN THE WORK OF GALDOS PRIOR TO 1898

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial

Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

A Multilevel Functional Study of a SNAP25 At-Risk Variant for Bipolar Disorder and Schizophrenia

Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia: The FACE-SZ Cohort

Many people with chronic lymphocytic leukemia or small lymphocytic lymphoma benefit from ibrutinib treatment up to 8 years: a plain language summary

Prognostic role of beta-2 microglobulin (B2M) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients (pts) treated with ibrutinib (ibr)

Sepsis-related deaths in the at-risk population on the wards: attributable fraction of mortality in a large point-prevalence study

Relationship of JAK2V617F Allelic Burden (AB) to Demographics, Disease Characteristics, and Response to Therapy in Persist-1, a Randomized Phase III Study of Pacritinib (PAC) Versus Best Available Therapy (BAT) in Patients (pts) with Primary and Secondary Myelofibrosis (MF)

Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/µl

Outcomes in patients with myelofibrosis and RBC-transfusion dependence in the phase III PERSIST-1 study of pacritinib vs. best available therapy

Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): 60 week follow-up of the phase III PERSIST-1 trial

Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Outcomes in patients (pts) with baseline (BL) thrombocytopenia

Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF)

Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF)

Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings

Suchergebnisse filtern